Compare Becton Dickinson and Co (BDX) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Nasdaq100 ETF — how do they compare? Becton Dickinson and Co trades at $156.52 (market cap $41.51B), while Nasdaq100 ETF trades at $715.23. The key difference: Becton Dickinson and Co pays a 2.79% dividend while Nasdaq100 ETF pays none, and Nasdaq100 ETF is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | QQQ | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | — |
52-Week High | $185.39 | $746.16 |
52-Week Low | $135.49 | $553.88 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
QQQ, tracking the Nasdaq-100, trades at $711.79, down 1.9% over 24 hours amid a bearish technical signal. The ETF faces mixed sentiment with a 50/50 split in analyst ratings and news highlighting SpaceX's inclusion and competitive pressures from new funds like BlackRock's IQQ. Support sits near $700, with resistance at $717, while oscillators like the RSI remain neutral, suggesting indecision in the short term.
Outlook is cautious due to technical weakness and divided analyst views, though long-term exposure to tech giants offers growth potential. Risks include index concentration, fee competition, and macroeconomic shifts affecting rate-sensitive holdings, requiring careful monitoring of earnings trends from underlying companies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
